Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

PhRMA CEO Selection Day Nears Now That Election Day Is Past

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Trade association board is expected to finalize choice to succeed CEO Alan Holmer during Nov. 11-12 strategy session. Rep. Billy Tauzin (R-La.) is still viewed as the likely pick.

You may also be interested in...



PhRMA CEO Succession Appears Set: Timing Not Yet Final

The Pharmaceutical Research & Manufacturers of America is understood to have finalized its plans to name retiring Rep. Billy Tauzin (R-La.) as its next CEO

PhRMA CEO Succession Appears Set: Timing Not Yet Final

The Pharmaceutical Research & Manufacturers of America is understood to have finalized its plans to name retiring Rep. Billy Tauzin (R-La.) as its next CEO

PhRMA Starts Over In CEO Search After Tauzin Negotiations End

Louisiana Republican breaks off negotiations with trade association amid negative media attention. Rep. Joe Barton will take the helm of the Energy & Commerce Committee.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS058204

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By